Rathbones Group PLC Sells 27,010 Shares of Pfizer Inc. $PFE

Rathbones Group PLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 5.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 447,525 shares of the biopharmaceutical company’s stock after selling 27,010 shares during the quarter. Rathbones Group PLC’s holdings in Pfizer were worth $11,143,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Mattern Wealth Management LLC lifted its stake in Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares during the last quarter. Peak Asset Management LLC raised its stake in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares during the last quarter. Quest Investment Management LLC raised its stake in shares of Pfizer by 1.3% during the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after acquiring an additional 405 shares during the last quarter. Community Bank & Trust Waco Texas raised its stake in shares of Pfizer by 0.6% during the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after acquiring an additional 412 shares during the last quarter. Finally, CVA Family Office LLC raised its stake in shares of Pfizer by 3.3% during the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 413 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Barclays initiated coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Monday, March 2nd. Guggenheim raised their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, UBS Group initiated coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.19.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.85 on Tuesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $28.75. The firm has a fifty day simple moving average of $27.13 and a 200 day simple moving average of $25.87. The company has a market capitalization of $158.35 billion, a PE ratio of 20.48 and a beta of 0.43. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the firm earned $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.